TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Q-linea AB ( (SE:QLINEA) ).
Q-linea AB announced the outcome of its rights issue, which was subscribed to 97.1 percent, raising approximately SEK 312 million before transaction costs. This capital increase will significantly enhance Q-linea’s financial position, potentially impacting its market operations and stakeholder interests, especially considering the dilution effect of approximately 66 percent.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.50 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a company listed on Nasdaq Stockholm, operating in the biotechnology sector. It focuses on developing and providing advanced diagnostic solutions, particularly in the field of infectious diseases.
Average Trading Volume: 13,050
Technical Sentiment Signal: Sell
Current Market Cap: SEK467.4M
For an in-depth examination of QLINEA stock, go to TipRanks’ Overview page.